Related Experiment Videos
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report
E Kurakawa1, I Kasuga, S Ishizuka
1First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Abstract:
A newly approved oral fluoropyrimidine, TS-1, is a dihydropyrimide dehydrogenase (DPD)-inhibiting fluoropyrimidine (DIF) drug. We describe a case of interstitial pneumonia probably caused by TS-1. A peripheral blood lymphocytes stimulating test (DLST) with TS-1 demonstrated a substantial positive reaction. So far only three cases of TS-1-induced interstitial pneumonia have been reported but the relationship between interstitial pneumonia and TS-1 was demonstrated only in this case. Considering that interstitial pneumonia has also been reported with 5-FU, it is necessary in the future to clarify which component of this drug is directly related to interstitial pneumonia.
Insights
A new oral cancer drug, TS-1, may cause interstitial pneumonia. A lymphocyte test confirmed TS-1
Area of Science:
- Oncology
- Pharmacology
Background:
- TS-1 is a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibiting fluoropyrimidine (DIF) drug.
- Interstitial pneumonia is a serious potential adverse event associated with chemotherapy.
Observation:
- This report details a patient who developed interstitial pneumonia.
- The patient was receiving the newly approved oral fluoropyrimidine, TS-1.
- A lymphocyte stimulating test (DLST) showed a significant positive reaction to TS-1.
Findings:
- The case presents strong evidence suggesting TS-1 as the probable cause of interstitial pneumonia.
- This is one of only a few reported cases linking TS-1 to interstitial pneumonia.
- The diagnostic lymphocyte test provides a direct link between the drug and the adverse reaction.
Implications:
- Further research is needed to determine which component of TS-1 is responsible for interstitial pneumonia.
- Understanding the specific drug component causing this adverse effect is crucial for patient safety.
- This finding may inform future drug development and treatment protocols for fluoropyrimidine-based therapies.